GET DAILY SIGNALSDexCom (DXCM) Reports 11% Revenue Growth in Q3 2026, Raises Full-Year Outlook
Key Takeaways
- DexCom reported third quarter 2026 revenue of $1.34 billion, up 11% year over year on both a reported and organic basis.
- Adjusted (non-GAAP) earnings per share came in at $0.73, beating the analyst consensus estimate of $0.67 by roughly 8%.
- U.S. revenue grew 14% to about $970 million, while international revenue rose 5% to roughly $375 million.
- Management raised its full-year 2026 revenue guidance to $5.20–$5.25 billion, implying 12%–13% growth.
- Non-GAAP operating margin expanded to approximately 24%, and adjusted EBITDA margin reached about 32%.
- Shares climbed roughly 2% in after-hours trading following the release.
Why These Results Matter
DexCom stands out as a leader in continuous glucose monitoring systems that allow people with diabetes to track levels in real time. Its quarterly updates serve as a useful gauge of demand for diabetes technology and the company's efforts to broaden access. After a solid first half of 2026, attention turned to whether growth could hold in double digits, market share could be defended, and margins could keep improving. The quarter also highlighted potential reimbursement changes, especially around Medicare coverage for certain type 2 diabetes patients, which could expand the long-term opportunity.
Q3 Results in Detail
For the period ended September 30, 2026, total revenue reached $1.34 billion, an 11% increase from $1.21 billion a year earlier. U.S. sales hit roughly $970 million, up 14%, while international revenue came in near $375 million, up 5%. Slower international growth stemmed mainly from tough prior-year comparisons tied to reimbursement gains rather than any fundamental slowdown.
Adjusted earnings per share of $0.73 topped the $0.67 consensus. GAAP diluted EPS was $0.72. Adjusted EBITDA totaled $435.2 million, ahead of the roughly $424 million expected. Non-GAAP operating margin rose to about 24%, helped by manufacturing gains, lower freight costs, and the contribution from the G7 15-day sensor. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Full-year 2026 revenue guidance was lifted to $5.20–$5.25 billion from the prior $5.18–$5.25 billion range, with non-GAAP operating margin held near 24%.
Market Response and Outlook
Shares moved up about 2% in after-hours trading after the October 29 release. The reaction reflected the earnings beat, slight revenue outperformance, and the raised guidance. From what I see, investors viewed the results as confirmation that growth momentum remains steady despite lapping stronger international comparisons from last year.
Comments on reimbursement added support, with expectations for a CMS decision on coverage for non-insulin type 2 diabetes patients this year and possible rollout in mid-2027. Clinical data from the CONNECT trial, published in the New England Journal of Medicine, further bolstered the longer-term case.
Looking ahead, the G7 15-day rollout should continue driving revenue and margins, with nearly half of U.S. customers expected to convert by year-end. International launches are set for Canada in November and Japan early next year. Reimbursement expansion remains a key catalyst, while margin trends should benefit from efficiencies and normalized costs at the Ireland facility. The pipeline, including a next-generation sensor and the Stelo over-the-counter option, offers additional growth avenues, though foreign exchange and competition will stay in focus.
AI Tools in My Research Process
When analyzing earnings like these, I often turn to Tickeron’s AI-powered tools to quickly scan for patterns and compare performance across peers. The AI Screener helps surface relevant data points efficiently, and I’ve found the AI Daily Buy/Sell Signals and AI Trend Prediction Engine useful for gauging momentum in real time. These resources fit naturally into a broader review without replacing fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DXCM's Indicator enters downward trend
The Aroon Indicator for DXCM entered a downward trend on October 28, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 194 similar instances where the Aroon Indicator formed such a pattern. In 146 of the 194 cases the stock moved lower. This puts the odds of a downward move at 75%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DXCM as a result. In 57 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.
The Moving Average Convergence Divergence Histogram (MACD) for DXCM turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 33 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
DXCM moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DXCM crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXCM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where DXCM's RSI Indicator exited the oversold zone, 18 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 53%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where DXCM advanced for three days, in 204 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
DXCM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 27 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. DXCM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.506) is normal, around the industry mean (3.824). P/E Ratio (30.981) is within average values for comparable stocks, (1.677). Projected Growth (PEG Ratio) (1.332) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (6.988) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DXCM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of medical devices and glucose monitoring systems
Industry MedicalNursingServices
Advertisement